<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715089</url>
  </required_header>
  <id_info>
    <org_study_id>PM1503</org_study_id>
    <nct_id>NCT02715089</nct_id>
  </id_info>
  <brief_title>Precise Treatment in Hepatobiliary Cancers (PTHBC)</brief_title>
  <acronym>PTHBC</acronym>
  <official_title>Single Center, Single Arm, Open Study, to Explore and Evaluate the Precise Treatment in Hepatobiliary Cancers(PTHBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>3D Medicines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the precise treatment in hepatobiliary cancer
      patients and evaluate drug safety, progression free and overall survival. This trial study is
      based on genetic tests, then therapeutic target drugs are administered according to the
      genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications,
      or translocations) may benefit from precise treatment which targets particular genetic
      abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary
      cancer patients better.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The genetic tests are performed for the eligible subjects in this study, then therapeutic
      target drugs are administered according to the genetic test reports. While the precise
      treatments, follow-ups are conducted to evaluate the efficacy and safety of the target drugs
      for the subjects, until the overall survival.

      Study Type: Non-Interventional. Masking: Open Label.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Objective response rates (ORR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the percentage of patients whose tumors have a complete or partial response to treatment (RECIST v1.1) .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>8 months</time_frame>
    <description>Progression-free survival (PFS) is the time that passes from the day in which the patient is enrolled in the trial until the date on which disease &quot;progresses&quot; or the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>Overall survival (OS) is the duration from the day in which the patient is enrolled in the trial until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of Response (DOR) is the duration from the first assessment of the tumor was CR or PR to the time that the first assessment for PD (Progressive Disease) or date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the percentage of patients whose tumors have a complete or partial response，or stable disease to treatment (RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reaction (ADR)/Adverse Event (AE)</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Patients with treatment-related adverse events as assessed by CTC-AE v4.0.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Neoplasms</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <condition>Hepatobiliary Neoplasms</condition>
  <arm_group>
    <arm_group_label>Precise treatment</arm_group_label>
    <description>All patients should accept next-generation sequencing (NGS) test before treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Precise treatment</intervention_name>
    <description>During screening stage, all patients should accept next-generation sequencing (NGS) test.</description>
    <arm_group_label>Precise treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The samples, both tissue(s) and blood of patients should be provided for the next-generation
      sequencing (NGS) test before screening.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects : Hepatobiliary Cancer patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 65, male or female.

          -  Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV.

          -  Palliative care as the preferred.

          -  The result of next-generation sequencing (NGS) test show the patient has gene mutation
             and also can be treated by the right commercial products that have been approved by
             the China Food and Drug Administration (CFDA) or the Food and Drug Administration
             (FDA).

          -  ECOG performance status 0-2.

          -  Life expectancy ≥3 months.

          -  Voluntarily participate in the study and agree to sign informed consent form.

        Exclusion Criteria:

          -  Hepatobiliary cancer patient with stageI-III, or with any of the following items will
             not be eligible for screening.Such as, suitable for the treatment of radical
             resection, radical resection but evaluation unmeasurable.

          -  The result of NGS test show the patient has no gene mutation, or has gene mutation but
             no medicine.

          -  ECOG performance status ≥ 3.

          -  Female patients who are pregnant or not using a contraceptive method of birth control.

          -  History or presence of serious cardiovascular or cerebrovascular abnormalities.

          -  Abnormalities of the hepatic or renal functions, such as jaundice, ascites, bilirubin
             ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3 (according
             to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events
             [CTC-AE] v4.0), creatinine ratio &gt; 3.5g/24 hours, renal failure.

          -  Persistent infection &gt; grade 2 (according to National Cancer Institute [NCI] Common
             Terminology Criteria for Adverse Events [CTC-AE] v4.0).

          -  Patient has underwent a major operation 4 weeks prior to screening or has not yet
             recovered from the operation.

          -  Patient with epilepsy, known or untreated brain metastases.

          -  The presence of wounds, ulcers or fractures that can not be healed, or with a past
             history of transplantation.

          -  The presence of bleeding events ≥grade 3 (according to National Cancer Institute [NCI]
             Common Terminology Criteria for Adverse Events [CTC-AE] v4.0) , present evidence or
             past history of coagulation dysfunction disorders.

          -  Known human immunodeficiency virus (HIV) infection history.

          -  Patient with drug abuse or unstable compliance.

          -  The presence of unresolved toxicity caused by any previous treatment/operation &gt; grade
             1 (according to National Cancer Institute [NCI] Common Terminology Criteria for
             Adverse Events [CTC-AE] v4.0), except alopecia, anemia or hypothyroidism).

          -  Investigator consider that the patient should not be enrolled in this study by careful
             assessment.

          -  The subjects participate in any other clinical trial in the meantime.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai-Tao Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Xie, Doctor</last_name>
    <phone>+86-15010856596</phone>
    <email>xieyuan1988@sina.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao-Bo Yang, Doctor</last_name>
    <phone>+86-13811675126</phone>
    <email>yangxiaobo67@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Xie, Doctor</last_name>
      <phone>+86-150-1085-6596</phone>
      <email>xieyuan1988@sina.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiao-Bo Yang, Doctor</last_name>
      <phone>+86-138-1167-5126</phone>
      <email>yangxiaobo67@pumch.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Hai-Tao Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NGS</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Biliary Tract Neoplasms</keyword>
  <keyword>Hepatobiliary Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data have the gene mutations information of patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

